Prognostic assay for metachronous colorectal cancer
OwnerJohannes Pieter Albert Baak, Emilius Adrianus Maria Jansseninventors
Life of this patent
Estimating the term…
Abstract
The invention provides a prognostic assay for metachronous colorectal carcinoma, which assay comprises obtaining a colorectal mucosa tissue biopsy sample taken from a human or non-human mammalian subject, and determining the average longest nuclear axis for a set of elongate nuclei in elongate cells in dysplastic tissue within said sample.
Claims15
A prognostic assay for metachronous colorectal carcinoma, which assay comprises obtaining a colorectal mucosa tissue biopsy sample taken from a human or nonhuman mammalian subject, and determining the average longest nuclear axis for a set of elongate nuclei in elongate cells in dysplastic tissue within said sample.
A biopsy tissue evaluation method comprising:
- obtaining a section of a colorectal mucosa tissue biopsy sample presenting a transverse section through at least one gland;
- staining cell nuclei in said section;
- generating a microscope image of said section;
- selecting a set of longitudinally cut elongate cells with elongate nuclei in said image;
- and determining the average longest nuclear axis of said selected set of cells.
An assay for MPECs cells in a colorectal mucosa tissue biopsy sample, said assay comprising analyzing said sample for the presence or absence of biomarkers for MPECs.
A prognostic assay for metachronous colorectal carcinoma in a human or non-human mammalian subject, said assay comprising:
- contacting a tissue or fluid sample from said subject with a reagent capable of binding to or reacting with a protein biomarker the increased or decreased production whereof is characteristic of MPECs positive subjects;
- determining the level of binding or reaction by said reagent and thereby assessing such subject as being of high risk or not high risk of development of metachronous colorectal carcinoma.
Dependencies are inferred from the claim text.